Oncosuppressor methylation: A possible key role in colon metastatic progression

Journal of Cellular Physiology

Volumn 226, Issue 7, 2011, Pages 1934-1939

  Tommasi, Stefania ^a   Pinto, Rosamaria ^a   Petriella, Daniela ^a   Pilato, Brunella ^a   Lacalamita, Rosanna ^a   Santini, Daniele ^b   Zito, Francesco ^a   Colucci, Giuseppe ^a   Paradiso, Angelo ^a   Silvestris, Nicola ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA;

ADULT; AGED; ARTICLE; CANCER GROWTH; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CLUSTER ANALYSIS; COLONIC NEOPLASMS; DISEASE PROGRESSION; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTORS, RETINOIC ACID; TUMOR SUPPRESSOR PROTEINS;

EID: 79955033074     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22524     Document Type: Article

References (19)

1. NCCN. 2010. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer v.2. 2010. Available at.
2. Bardelli A, Siena S. 2010. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28:1254-1261.
3. Blanco D, Vicent S, Fraga MF, Fernandez-Garcia I, Freire J, Lujambio A, Esteller M, Ortiz-de-Solorzano C, Pio R, Lecanda F, Montuenga LM. 2007. Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway. Neoplasia 9:840-852.
4. Brambilla E, Gazzeri S, Moro D, et al. 1999. Alterations of Rb pathway (Rb-p16INK4-cyclin D1) in preinvasive bronchial lesions. Clin Cancer Res 5:243-250.
5. Côté S, Sinnett D, Momparler RL. 1998. Demethylation by 5-aza-2'-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells. Anticancer Drugs 9:743-750.
6. Esteller M. 2008. Epigenetics in cancer. N Engl J Med 358:1148-1159.
7. Fendri A, Masmoudi A, Khabir A, et al. 2009. Inactivation of RASSF1A, RARbeta2 and DAP-kinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Cancer Biol Ther 8:444-451.
8. Hase K, Shatney C, Johnson D, et al. 1993. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum 36:627-635.
9. Kim MS, Lee J, Sidransky D. 2010. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev 29:181-206.
10. Laurent-Puig P, Cayre A, Manceau G, et al. 2009. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type K-RAS metastatic colon cancer. J Clin Oncol 27:5924-5930.
11. Lee S, Cho N-Y, Yoo EJ, et al. 2008. CpG island methylator phenotype in colorectal cancers. Comparison of the new and classic CpG island methylator phenotype marker panels. Arch Pathol Lab Med 132:1657-1665.
12. Liu Y, Gao W, Siegfried JM, et al. 2007. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers. BMC Cancer 7:74.
13. Sah JF, Eckert RL, Chandraratna RA, Rorke EA. 2002. Retinoids suppress epidermal growth factor-associated cell proliferation by inhibiting epidermal growth factor receptor-dependent ERK1/2 activation. J Biol Chem 277:9728-35.
14. Shen L, Toyota M, Kondo Y, et al. 2007. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 104:18654-18659.
15. Silvestris N, Tommasi S, Santini D, et al. 2009. K-RAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: An open issue. Expert Opin Biol Ther 9:565-577.
16. Toyota M, Ahuja N, Ohe-Toyota M, et al. 1999. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96:8681-8686.
17. van Engeland M, Roemen GM, Brink M, et al. 2002. K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene 21:3792-3795.
18. Yagi K, Akagi K, Hayashi H, et al. 2010. Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res 16:21-33.
19. Zlobec I, Lugli A. 2009. Invasive front of colorectal cancer: Dynamic interface of pro-/anti-tumor factors. World J Gastroenterol 15:5898-5906.